Aberrant DNA methylation of P16, MGMT, and hMLH1 genes in combination with MTHFR C677T genetic polymorphism in esophageal squamous cell carcinoma

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 1, 2008, Pages 118-125

  Wang, JianMing ^a,b   Sasco, Annie J ^c   Fu, ChaoWei ^a   Xue, HengChuan ^b   Guo, GuoPing ^b   Hua, ZhaoLai ^b   Zhou, Qing ^b   Jiang, QingWu ^a   Xu, Biao ^a  

^a FUDAN UNIVERSITY   (China)

^b Yangzhong Cancer Research Institute   (China)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN MLH1; PROTEIN P16;

ADULT; AGED; ARTICLE; CANCER TISSUE; CHINA; CONFIDENCE INTERVAL; CPG ISLAND; DNA METHYLATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENETIC POLYMORPHISM; HISTOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; PROMOTER REGION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CARCINOMA, SQUAMOUS CELL; CHINA; CPG ISLANDS; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; ESOPHAGEAL NEOPLASMS; FEMALE; GENES, P16; GENOTYPE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 38849089235     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-0733     Document Type: Article

References (48)

1. Layke JC, Lopez PP. Esophageal cancer: a review and update. Am Fam Physician 2006;73:2187-94.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
3. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349:2241-52.
4. Gallus S, La Vecchia C. Is there a link between diet and esophageal cancer? Nat Clin Pract Gastroenterol Hepatol 2007;4:2-3.
5. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-6.
6. Wang JM, Xu B, Rao JY, Shen HB, Xue HC, Jiang QW. Diet habits, alcohol drinking, tobacco smoking, green tea drinking, and the risk of esophageal squamous cell carcinoma in the Chinese population. Eur J Gastroenterol Hepatol 2007;19:171-6.
7. Wei WQ, Abnet CC, Qiao YL, et al. Prospective study of serum selenium concentrations and esophageal and gastric cardia cancer, heart disease, stroke, and total death. Am J Clin Nutr 2004;79:80-5.
8. Kim YI. Role of folate in colon cancer development and progression. J Nutr 2003;133:S3731-9.
9. Larsson SC, Giovannucci E, Wolk A. Folate intake, MTHFR polymorphisms, and risk of esophageal, gastric, and pancreatic cancer: a meta-analysis. Gastroenterology 2006;131:1271-83.
10. Kim YI. Will mandatory folic acid fortification prevent or promote cancer? Am J Clin Nutr 2004;80:1123-8.
11. Duthie SJ. Folic acid deficiency and cancer: mechanisms of DNA instability. Br Med Bull 1999;55:578-92.
12. Das PM, Singal R. DNA methylation and cancer. J Clin Oncol 2004;22:4632-42.
13. Deltour S, Chopin V, Leprince D. Epigenetics and cancer. Med Sci (Paris) 2005;21:405-11.
14. Song C, Xing D, Tan W, Wei Q, Lin D. Methylenetetrahydrofolate reductase polymorphisms increase risk of esophageal squamous cell carcinoma in a Chinese population. Cancer Res 2001;61:3272-5.
15. Zhang J, Zotz RB, Li Y, et al. Methylenetetrahydrofolate reductase C677T polymorphism and predisposition towards esophageal squamous cell carcinoma in a German Caucasian and a northern Chinese population. J Cancer Res Clin Oncol 2004;130:574-80.
16. Sato F, Meltzer SJ. CpG island hypermethylation in progression of esophageal and gastric cancer. Cancer 2006;106:483-93.
17. Macaluso M, Paggi MG, Giordano A. Genetic and epigenetic alterations as hallmarks of the intricate road to cancer. Oncogene 2003;22:6472-8.
18. Zhang ZL, Yang JL, Lu FL, Yin XS, Luo ZG, Wang MR. Mortality rate of malignant tumors in Yangzhong County. Zhonghua Zhong Liu Za Zhi 1988;10:102-4.
19. Wang JM, Xu B, Hsieh CC, Jiang QW. Longitudinal trends of stomach cancer and esophageal cancer in Yangzhong County: a high-incidence rural area of China. Eur J Gastroenterol Hepatol 2005;17:1339-44.
20. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-6.
21. Yang YX, Wang GY, Pan XC. Zhong Guo Shi Wu Cheng Fen Biao 2002. Beijing: Peking University Medical Press; 2002. p. 326-8.
22. Yang YX, He M, Pan XC. Zhong Guo Shi Wu Cheng Fen Biao 2004. Beijing: Peking University Medical Press; 2005. p. 78-215.
23. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer 2004;4:988-93.
24. Gius D, Bradbury CM, Sun L, et al. The epigenome as a molecular marker and target. Cancer 2005;104:1789-93.
25. Momparler RL, Bovenzi V. DNA methylation and cancer. J Cell Physiol 2000;183:145-54.
26. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004;429:457-63.
27. Xing EP, Nie Y, Wang LD, Yang GY, Yang CS. Aberrant methylation of p16INK4a and deletion of p15INK4b are frequent events in human esophageal cancer in Linxian, China. Carcinogenesis 1999;20:77-84.
28. Nie Y, Liao J, Zhao X, et al. Detection of multiple gene hypermethylation in the development of esophageal squamous cell carcinoma. Carcinogenesis 2002;23:1713-20.
29. Hibi K, Taguchi M, Nakayama H, et al. Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma. Clin Cancer Res 2001;7:3135-8.
30. Rocco JW, Sidransky D. p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res 2001;264:42-55.
31. Christmann M, Tomicic MT, Roos WP, Kaina B. Mechanisms of human DNA repair: an update. Toxicology 2003;193:3-34.
32. Liu Y, Lan Q, Siegfried JM, Luketich JD, Keohavong P. Aberrant promoter methylation of p16 and MGMT genes in lung tumors from smoking and never-smoking lung cancer patients. Neoplasia 2006;8:46-51.
33. Hsu HS, Wen CK, Tang YA, et al. Promoter hypermethylation is the predominant mechanism in hMLH1 and hMSH2 deregulation and is a poor prognostic factor in nonsmoking lung cancer. Clin Cancer Res 2005;11:5410-6.
34. Geddert H, Kiel S, Iskender E, et al. Correlation of hMLH1 and HPP1 hypermethylation in gastric, but not in esophageal and cardiac adenocarcinoma. Int J Cancer 2004;110:208-11.
35. 6-methylguanine-DNA methyltransferase (MGMT) promotor hypermethylation in esophageal adenocarcinoma. Int J Cancer 2006;119:264-8.
36. 6-methylguanine-DNA methyltransferase in esophageal squamous cell carcinomas and its reactivation in cell lines. Int J Oncol 2005;26:615-22.
37. Vasavi M, Ponnala S, Gujjari K, et al. DNA methylation in esophageal diseases including cancer: special reference to hMLH1 gene promoter status. Tumori 2006;92:155-62.
38. Murrell A, Rakyan VK, Beck S. From genome to epigenome. Hum Mol Genet 2005;14 Spec No 1:R3-10.
39. Rodenhiser D, Mann M. Epigenetics and human disease: translating basic biology into clinical applications. CMAJ 2006;174:341-8.
40. Sutherland JE, Costa M. Epigenetics and the environment. Ann N Y Acad Sci 2003;983:151-60.
41. Slattery ML, Curtin K, Sweeney C, et al. Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer. Int J Cancer 2007;120:656-63.
42. Mason JB, Dickstein A, Jacques PF, et al. A temporal association between folic acid fortification and an increase in colorectal cancer rates may be illuminating important biological principles: a hypothesis. Cancer Epidemiol Biomarkers Prev 2007;16:1325-9.
43. Baggott JE, Vaughn WH, Juliana MM, Eto I, Krumdieck CL, Grubbs CJ. Effects of folate deficiency and supplementation on methylnitrosourea-induced rat mammary tumors. J Natl Cancer Inst 1992;84:1740-4.
44. Kotsopoulos J, Sohn KJ, Martin R, et al. Dietary folate deficiency suppresses N-methyl-N-nitrosourea-induced mammary tumorigenesis in rats. Carcinogenesis 2003;24:937-44.
45. Friso S, Choi SW, Girelli D, et al. A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci USA 2002;99:5606-11.
46. Marugame T, Tsuji E, Kiyohara C, et al. Relation of plasma folate and methylenetetrahydrofolate reductase C677T polymorphism to colorectal adenomas. Int J Epidemiol 2003;32:64-6.
47. Bremnes RM, Sirera R, Camps C. Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up? Lung Cancer 2005;49:1-12.
48. Ramirez JL, Sarries C, de Castro PL, et al. Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients. Cancer Lett 2003;193:207-16.